David A. Siegel Ionis Pharmaceuticals Inc Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,667,611 shares of IONS stock, worth $195 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
2,667,611
Previous 2,092,011
27.51%
Holding current value
$195 Million
Previous $63.1 Million
66.99%
% of portfolio
0.23%
Previous 0.15%
Shares
32 transactions
Others Institutions Holding IONS
# of Institutions
416Shares Held
149MCall Options Held
1.72MPut Options Held
722K-
Vanguard Group Inc Valley Forge, PA16.7MShares$1.22 Billion0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16MShares$1.17 Billion0.4% of portfolio
-
Capital World Investors Los Angeles, CA12.5MShares$916 Million0.08% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$754 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.85MShares$574 Million7.06% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $10.4B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...